Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919113 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
A Phase 2 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT00919113 is a Phase 2 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 98 participants.
The verdict
NCT00919113, a Phase 2 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
Interventions
- DRUG Placebo
- DRUG 2% sodium chondroitin sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00919113
The ClinicalTrials.gov registry entry for NCT00919113 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00919113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00919113 about?
NCT00919113 is a clinical study titled "Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome". A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
What is the current status of trial NCT00919113?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2009-07. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00919113?
The interventions under investigation include: Placebo (DRUG), 2% sodium chondroitin sulfate (DRUG).
Who is sponsoring clinical trial NCT00919113?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.